{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T16:57:28Z","timestamp":1770310648137,"version":"3.49.0"},"posted":{"date-parts":[[2026,1,19]]},"group-title":"In Review","reference-count":56,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,1,8]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Background\n A pathogenetic role of glial cells has been established virtually in all neurodegenerative disorders. In Alzheimer's disease (AD), together with \u03b2-amyloid deposition and the formation of fibrillary tangles, neuroinflammation contributes to neuronal dysfunction associated with the disease. Thus, selective control of glial cell activation becomes part of the multifactorial therapeutic strategies in AD. Astrocytes and microglia are highly heterogeneous in their morphology and physiology, and this diversity underlies their distinct functional states in the central nervous system. In AD, they exhibit dynamic and stage-dependent pathological phenotypes during disease onset and progression. In this context, investigating the disease-associated glia signature would provide significant progress in understanding pathological mechanisms and in the development of beneficial treatments. The use of human induced pluripotent stem cells (iPSCs) to study CNS cell alterations during brain pathologies greatly improves the possibility of identifying human- and cell-specific changes likely contributing to AD progression.\nMethods\n Here we used isolated glia cultures and neuron\/glia cocultures derived from iPSC carrying a mutation in the presenilin-1 (PSEN1) gene to investigate AD-related microglia and astrocyte impairments and their contribution to neuronal degeneration.\nResults\n Microglia from AD iPSCs showed compromised functional properties while astrocytes exhibited a predominant fibroblast-like phenotype and increased expression of inflammatory markers. Consistently, transcriptomic derangement for reactive phenotype-related genes, correlating with cell morphology, allowed to well distinguish AD astrocytes from control cells. We finally observed that glia-specific AD-related changes affected some neuronal properties in mixed neuron\/glia cocultures, while the presence of the mutation in both cell population triggered a dramatic neuronal damage, involving neuronal network degradation, synaptic alterations and impaired electrophysiological properties. On the other hand, the replacement of AD with healthy glia was not sufficient to protect from neurodegeneration, suggesting the pivotal role of mutated PSEN1 in neurons.\nConclusions\n We herein succeeded in reproducing crucial AD-related changes in iPSC-derived\n                  <italic>in vitro<\/italic>\n                  models providing new insights in the neuropathological communication amongst brain cells, thus representing a promising tool to deepen disease mechanisms and develop neuroprotective treatments.\n                <\/p>","DOI":"10.21203\/rs.3.rs-8549806\/v1","type":"posted-content","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T16:44:23Z","timestamp":1768841063000},"source":"Crossref","is-referenced-by-count":0,"title":["Glial and Neuronal Alzheimer's Disease-Related Alterations Reproduced in Human Induced Pluripotent Stem Cells With Presenilin-1 Mutation"],"prefix":"10.21203","author":[{"given":"Davide","family":"Comolli","sequence":"first","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Murari","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milica","family":"Cerovic","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liviu","family":"Soltuzu","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Liao","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Seminara","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Craparotta","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Fumagalli","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Balducci","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluigi","family":"Forloni","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"De Paola","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"1. Zhang L, Chen C, Mak MS, Lu J, Wu Z, Chen Q, et al. Advance of sporadic Alzheimer\u2019s disease animal models. Medicinal Research Reviews. 2020;40:431\u201358. https:\/\/doi.org\/10.1002\/med.21624","DOI":"10.1002\/med.21624"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"2. Moradi S, Mahdizadeh H, \u0160ari\u0107 T, Kim J, Harati J, Shahsavarani H, et al. Research and therapy with induced pluripotent stem cells (iPSCs): social, legal, and ethical considerations. Stem Cell Res Ther. 2019;10:341. https:\/\/doi.org\/10.1186\/s13287-019-1455-y","DOI":"10.1186\/s13287-019-1455-y"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"3. Valadez-Barba V, Cota-Coronado A, Hern\u00e1ndez-P\u00e9rez OR, Lugo-Fabres PH, Padilla-Camberos E, D\u00edaz NF, et al. iPSC for modeling neurodegenerative disorders. Regenerative Therapy. 2020;15:332\u20139. https:\/\/doi.org\/10.1016\/j.reth.2020.11.006","DOI":"10.1016\/j.reth.2020.11.006"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"4. Heneka MT, Carson MJ, Khoury JE, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer\u2019s disease. The Lancet Neurology. 2015;14:388\u2013405. https:\/\/doi.org\/10.1016\/S1474-4422(15)70016-5","DOI":"10.1016\/S1474-4422(15)70016-5"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"5. Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016;353:777\u201383. https:\/\/doi.org\/10.1126\/science.aag2590","DOI":"10.1126\/science.aag2590"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"6. Penney J, Ralvenius WT, Tsai L-H. Modeling Alzheimer\u2019s disease with iPSC-derived brain cells. Mol Psychiatry. 2020;25:148\u201367. https:\/\/doi.org\/10.1038\/s41380-019-0468-3","DOI":"10.1038\/s41380-019-0468-3"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"7. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid \u03b2-peptide. Nat Rev Mol Cell Biol. 2007;8:101\u201312. https:\/\/doi.org\/10.1038\/nrm2101","DOI":"10.1038\/nrm2101"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"8. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391:387\u201390. https:\/\/doi.org\/10.1038\/34910","DOI":"10.1038\/34910"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"9. Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D\u2019Avanzo C, et al. A three-dimensional human neural cell culture model of Alzheimer\u2019s disease. Nature. 2014;515:274\u20138. https:\/\/doi.org\/10.1038\/nature13800","DOI":"10.1038\/nature13800"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"10. Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, et al. Probing sporadic and familial Alzheimer\u2019s disease using induced pluripotent stem cells. Nature. 2012;482:216\u201320. https:\/\/doi.org\/10.1038\/nature10821","DOI":"10.1038\/nature10821"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"11. Gonzalez C, Armijo E, Bravo-Alegria J, Becerra-Calixto A, Mays CE, Soto C. Modeling amyloid beta and tau pathology in human cerebral organoids. Mol Psychiatry. 2018;23:2363\u201374. https:\/\/doi.org\/10.1038\/s41380-018-0229-8","DOI":"10.1038\/s41380-018-0229-8"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"12. Raja WK, Mungenast AE, Lin Y-T, Ko T, Abdurrob F, Seo J, et al. Self-Organizing 3D Human Neural Tissue Derived from Induced Pluripotent Stem Cells Recapitulate Alzheimer\u2019s Disease Phenotypes. Padmanabhan J, editor. PLoS ONE. 2016;11:e0161969. https:\/\/doi.org\/10.1371\/journal.pone.0161969","DOI":"10.1371\/journal.pone.0161969"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"13. Cerovic M, Forloni G, Balducci C. Neuroinflammation and the Gut Microbiota: Possible Alternative Therapeutic Targets to Counteract Alzheimer\u2019s Disease? Front Aging Neurosci. 2019;11:284. https:\/\/doi.org\/10.3389\/fnagi.2019.00284","DOI":"10.3389\/fnagi.2019.00284"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"14. Balducci C, Forloni G. Novel targets in Alzheimer\u2019s disease: A special focus on microglia. Pharmacological Research. 2018;130:402\u201313. https:\/\/doi.org\/10.1016\/j.phrs.2018.01.017","DOI":"10.1016\/j.phrs.2018.01.017"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"15. Forloni G, Balducci C. Alzheimer\u2019s Disease, Oligomers, and Inflammation. Journal of Alzheimer\u2019s Disease. 2018;62:1261\u201376. https:\/\/doi.org\/10.3233\/JAD-170819","DOI":"10.3233\/JAD-170819"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"16. Jones VC, Atkinson-Dell R, Verkhratsky A, Mohamet L. Aberrant iPSC-derived human astrocytes in Alzheimer\u2019s disease. Cell Death Dis. 2017;8:e2696\u2013e2696. https:\/\/doi.org\/10.1038\/cddis.2017.89","DOI":"10.1038\/cddis.2017.89"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"17. Lawrence JM, Schardien K, Wigdahl B, Nonnemacher MR. Roles of neuropathology-associated reactive astrocytes: a systematic review. acta neuropathol commun. 2023;11:42. https:\/\/doi.org\/10.1186\/s40478-023-01526-9","DOI":"10.1186\/s40478-023-01526-9"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"18. Oksanen M, Petersen AJ, Naumenko N, Puttonen K, Lehtonen \u0160, Gubert Oliv\u00e9 M, et al. PSEN1 Mutant iPSC-Derived Model Reveals Severe Astrocyte Pathology in Alzheimer\u2019s Disease. Stem Cell Reports. 2017;9:1885\u201397. https:\/\/doi.org\/10.1016\/j.stemcr.2017.10.016","DOI":"10.1016\/j.stemcr.2017.10.016"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"19. Ismail A, Al-kuraishy HM, Al-Gareeb AI, Albuhadily AK, Yassen ASA, Alexiou A, et al. Astrocyte response in Alzheimer\u2019s disease: Good or bad? Brain Research. 2025;1868:149971. https:\/\/doi.org\/10.1016\/j.brainres.2025.149971","DOI":"10.1016\/j.brainres.2025.149971"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"20. McQuade A, Coburn M, Tu CH, Hasselmann J, Davtyan H, Blurton-Jones M. Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Mol Neurodegeneration. 2018;13:67. https:\/\/doi.org\/10.1186\/s13024-018-0297-x","DOI":"10.1186\/s13024-018-0297-x"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"21. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34:525\u20137. https:\/\/doi.org\/10.1038\/nbt.3519","DOI":"10.1038\/nbt.3519"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"22. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research. 2015;43:e47\u2013e47. https:\/\/doi.org\/10.1093\/nar\/gkv007","DOI":"10.1093\/nar\/gkv007"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"23. Chen Y, Chen L, Lun ATL, Baldoni PL, Smyth GK. edgeR v4: powerful differential analysis of sequencing data with expanded functionality and improved support for small counts and larger datasets. Nucleic Acids Research. 2025;53:gkaf018. https:\/\/doi.org\/10.1093\/nar\/gkaf018","DOI":"10.1093\/nar\/gkaf018"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"24. Wu D, Smyth GK. Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Research. 2012;40:e133\u2013e133. https:\/\/doi.org\/10.1093\/nar\/gks461","DOI":"10.1093\/nar\/gks461"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"25. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350. https:\/\/doi.org\/10.1073\/pnas.0506580102","DOI":"10.1073\/pnas.0506580102"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"26. Keil SA, Jansson D, Braun M, Iliff JJ. Glymphatic dysfunction in Alzheimer\u2019s disease: A critical appraisal. Science. 2025;389:eadv8269. https:\/\/doi.org\/10.1126\/science.adv8269","DOI":"10.1126\/science.adv8269"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"27. Taylor X, Cisternas P, Jury N, Martinez P, Huang X, You Y, et al. Activated endothelial cells induce a distinct type of astrocytic reactivity. Commun Biol. 2022;5:282. https:\/\/doi.org\/10.1038\/s42003-022-03237-8","DOI":"10.1038\/s42003-022-03237-8"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"28. Lian H, Yang L, Cole A, Sun L, Chiang AC-A, Fowler SW, et al. NF\u03baB-Activated Astroglial Release of Complement C3 Compromises Neuronal Morphology and Function Associated with Alzheimer\u2019s Disease. Neuron. 2015;85:101\u201315. https:\/\/doi.org\/10.1016\/j.neuron.2014.11.018","DOI":"10.1016\/j.neuron.2014.11.018"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"29. Endo F, Kasai A, Soto JS, Yu X, Qu Z, Hashimoto H, et al. Molecular basis of astrocyte diversity and morphology across the CNS in health and disease. Science. 2022;378:eadc9020. https:\/\/doi.org\/10.1126\/science.adc9020","DOI":"10.1126\/science.adc9020"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"30. Endo F. Deciphering the spectrum of astrocyte diversity: Insights into molecular, morphological, and functional dimensions in health and neurodegenerative diseases. Neuroscience Research. 2025;210:1\u201310. https:\/\/doi.org\/10.1016\/j.neures.2024.07.008","DOI":"10.1016\/j.neures.2024.07.008"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"31. Khakh BS, Deneen B. The Emerging Nature of Astrocyte Diversity. Annu Rev Neurosci. 2019;42:187\u2013207. https:\/\/doi.org\/10.1146\/annurev-neuro-070918-050443","DOI":"10.1146\/annurev-neuro-070918-050443"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"32. Rodr\u00edguez JJ, Zallo F, Gardenal E, Cabot J, Busquets X. Prominent and conspicuous astrocyte atrophy in human sporadic and familial Alzheimer\u2019s disease. Brain Struct Funct. 2023;228:2103\u201313. https:\/\/doi.org\/10.1007\/s00429-023-02707-x","DOI":"10.1007\/s00429-023-02707-x"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"33. Yue Q, Man Hoi M. Emerging roles of astrocytes in blood-brain barrier disruption upon amyloid-beta insults in Alzheimer\u2019s disease. Neural Regen Res. 2023;0:0. https:\/\/doi.org\/10.4103\/1673-5374.367832","DOI":"10.4103\/1673-5374.367832"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"34. Kulijewicz-Nawrot M, Verkhratsky A, Chv\u00e1tal A, Sykov\u00e1 E, Rodr\u00edguez JJ. Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer\u2019s disease. Journal of Anatomy. 2012;221:252\u201362. https:\/\/doi.org\/10.1111\/j.1469-7580.2012.01536.x","DOI":"10.1111\/j.1469-7580.2012.01536.x"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"35. Matias I, Morgado J, Gomes FCA. Astrocyte Heterogeneity: Impact to Brain Aging and Disease. Front Aging Neurosci. 2019;11:59. https:\/\/doi.org\/10.3389\/fnagi.2019.00059","DOI":"10.3389\/fnagi.2019.00059"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"36. Preman P, Alfonso-Triguero M, Alberdi E, Verkhratsky A, Arranz AM. Astrocytes in Alzheimer\u2019s Disease: Pathological Significance and Molecular Pathways. Cells. 2021;10:540. https:\/\/doi.org\/10.3390\/cells10030540","DOI":"10.3390\/cells10030540"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"37. Yeh C-Y, Vadhwana B, Verkhratsky A, Rodr\u00edguez JJ. Early Astrocytic Atrophy in the Entorhinal Cortex of a Triple Transgenic Animal Model of Alzheimer\u2019s Disease. ASN Neuro. 2011;3:AN20110025. https:\/\/doi.org\/10.1042\/AN20110025","DOI":"10.1042\/AN20110025"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"38. Verkhratsky A, Rodrigues JJ, Pivoriunas A, Zorec R, Semyanov A. Astroglial atrophy in Alzheimer\u2019s disease. Pflugers Arch - Eur J Physiol. 2019;471:1247\u201361. https:\/\/doi.org\/10.1007\/s00424-019-02310-2","DOI":"10.1007\/s00424-019-02310-2"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"39. Han J, Zhang Z, Zhang P, Yu Q, Cheng Q, Lu Z, et al. The roles of microglia and astrocytes in neuroinflammation of Alzheimer\u2019s disease. Front Neurosci. 2025;19:1575453. https:\/\/doi.org\/10.3389\/fnins.2025.1575453","DOI":"10.3389\/fnins.2025.1575453"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"40. Kim J, Yoo ID, Lim J, Moon J-S. Pathological phenotypes of astrocytes in Alzheimer\u2019s disease. Exp Mol Med. 2024;56:95\u20139. https:\/\/doi.org\/10.1038\/s12276-023-01148-0","DOI":"10.1038\/s12276-023-01148-0"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"41. Butovsky O, Weiner HL. Microglial signatures and their role in health and disease. Nat Rev Neurosci. 2018;19:622\u201335. https:\/\/doi.org\/10.1038\/s41583-018-0057-5","DOI":"10.1038\/s41583-018-0057-5"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"42. Hernang\u00f3mez M, Mestre L, Correa FG, Lor\u00eda F, Mecha M, I\u00f1igo PM, et al. CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation. Glia. 2012;60:1437\u201350. https:\/\/doi.org\/10.1002\/glia.22366","DOI":"10.1002\/glia.22366"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"43. Koning N, Swaab DF, Hoek RM, Huitinga I. Distribution of the Immune Inhibitory Molecules CD200 and CD200R in the Normal Central Nervous System and Multiple Sclerosis Lesions Suggests Neuron-Glia and Glia-Glia Interactions: Journal of Neuropathology and Experimental Neurology. 2009;68:159\u201367. https:\/\/doi.org\/10.1097\/NEN.0b013e3181964113","DOI":"10.1097\/NEN.0b013e3181964113"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"44. Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue L-F. Decreased expression of CD200 and CD200 receptor in Alzheimer\u2019s disease: A potential mechanism leading to chronic inflammation. Experimental Neurology. 2009;215:5\u201319. https:\/\/doi.org\/10.1016\/j.expneurol.2008.09.003","DOI":"10.1016\/j.expneurol.2008.09.003"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"45. Lawrence JM, Schardien K, Wigdahl B, Nonnemacher MR. Roles of neuropathology-associated reactive astrocytes: a systematic review. acta neuropathol commun. 2023;11:42. https:\/\/doi.org\/10.1186\/s40478-023-01526-9","DOI":"10.1186\/s40478-023-01526-9"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"46. Kim S, Chun H, Kim Y, Kim Y, Park U, Chu J, et al. Astrocytic autophagy plasticity modulates A\u03b2 clearance and cognitive function in Alzheimer\u2019s disease. Mol Neurodegeneration. 2024;19:55. https:\/\/doi.org\/10.1186\/s13024-024-00740-w","DOI":"10.1186\/s13024-024-00740-w"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"47. Ziff OJ, Parfitt GM, Jolly S, Casey JM, Granat L, Samra S, et al. Mutations in PSEN1 predispose inflammation in an astrocyte model of familial Alzheimer\u2019s disease through disrupted regulated intramembrane proteolysis. Mol Neurodegeneration. 2025;20:73. https:\/\/doi.org\/10.1186\/s13024-025-00864-7","DOI":"10.1186\/s13024-025-00864-7"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"48. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481\u20137. https:\/\/doi.org\/10.1038\/nature21029","DOI":"10.1038\/nature21029"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"49. Pekna M, Pekny M. The Complement System: A Powerful Modulator and Effector of Astrocyte Function in the Healthy and Diseased Central Nervous System. Cells. 2021;10:1812. https:\/\/doi.org\/10.3390\/cells10071812","DOI":"10.3390\/cells10071812"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"50. Popov A, Brazhe N, Morozova K, Yashin K, Bychkov M, Nosova O, et al. Mitochondrial malfunction and atrophy of astrocytes in the aged human cerebral cortex. Nat Commun. 2023;14:8380. https:\/\/doi.org\/10.1038\/s41467-023-44192-0","DOI":"10.1038\/s41467-023-44192-0"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"51. Badia-Soteras A, Heistek TS, Kater MSJ, Mak A, Negrean A, Van Den Oever MC, et al. Retraction of Astrocyte Leaflets From the Synapse Enhances Fear Memory. Biological Psychiatry. 2023;94:226\u201338. https:\/\/doi.org\/10.1016\/j.biopsych.2022.10.013","DOI":"10.1016\/j.biopsych.2022.10.013"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"52. Fehon RG, McClatchey AI, Bretscher A. Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol. 2010;11:276\u201387. https:\/\/doi.org\/10.1038\/nrm2866","DOI":"10.1038\/nrm2866"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"53. Supakul S, Murakami R, Oyama C, Shindo T, Hatakeyama Y, Itsuno M, et al. Mutual interaction of neurons and astrocytes derived from iPSCs with APP V717L mutation developed the astrocytic phenotypes of Alzheimer\u2019s disease. Inflamm Regener. 2024;44:8. https:\/\/doi.org\/10.1186\/s41232-023-00310-5","DOI":"10.1186\/s41232-023-00310-5"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"54. Priller C, Dewachter I, Vassallo N, Paluch S, Pace C, Kretzschmar HA, et al. Mutant Presenilin 1 Alters Synaptic Transmission in Cultured Hippocampal Neurons. Journal of Biological Chemistry. 2007;282:1119\u201327. https:\/\/doi.org\/10.1074\/jbc.M605066200","DOI":"10.1074\/jbc.M605066200"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"55. Maksour S, Finol-Urdaneta RK, Hulme AJ, Cabral-da-Silva MEC, Targa Dias Anastacio H, Balez R, et al. Alzheimer\u2019s disease induced neurons bearing PSEN1 mutations exhibit reduced excitability. Front Cell Neurosci. 2024;18:1406970. https:\/\/doi.org\/10.3389\/fncel.2024.1406970","DOI":"10.3389\/fncel.2024.1406970"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"56. Ghatak S, Dolatabadi N, Trudler D, Zhang X, Wu Y, Mohata M, et al. Mechanisms of hyperexcitability in Alzheimer\u2019s disease hiPSC-derived neurons and cerebral organoids vs isogenic controls. eLife. 2019;8:e50333. https:\/\/doi.org\/10.7554\/eLife.50333","DOI":"10.7554\/eLife.50333"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8549806\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8549806\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T03:55:04Z","timestamp":1770263704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8549806\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":56,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-8549806\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,1,19]]},"subtype":"preprint"}}